Friday, 31 Oct 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • VIDEO
  • House
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Health and Wellness > Promising BioNTech data on triple negative breast cancer treatment
Health and Wellness

Promising BioNTech data on triple negative breast cancer treatment

Last updated: December 15, 2024 8:21 am
Share
Promising BioNTech data on triple negative breast cancer treatment
SHARE

Researchers may have discovered a promising candidate for the next generation of immunotherapy drugs in the form of bispecific antibodies targeting two key proteins in cancer – PD1 or PD-L1 and VEGF. A recent small early trial presented at the San Antonio Breast Cancer Symposium by researchers working with BioNTech showcased positive results in patients with triple negative breast cancer using a bispecific compound called BNT-327. This compound, if further trials prove successful, could become a crucial part of treating not only triple negative breast cancer but potentially other types of cancer as well.

The development of bispecific antibodies targeting PD1 or PD-L1 and VEGF builds upon the groundbreaking discovery of checkpoint inhibitors in the 1990s. These inhibitors, such as Merck’s Keytruda, have revolutionized cancer treatment by stimulating the immune system to recognize and eliminate cancer cells. However, there is still room for improvement in this area. BioNTech co-founder and CMO Özlem Türeci believes that PD-L1 or PD1 and anti-VEGF bispecifics represent the next generation of checkpoint inhibitors that could further enhance cancer treatment.

The potential of bispecific antibodies targeting these proteins gained attention when Summit Therapeutics released data showing that their PD1 and VEGF bispecific antibody outperformed Keytruda in a Phase 3 trial for advanced lung cancer. While experts noted the impressive results, they also cautioned that further research is needed to determine if the drug can extend overall survival, a critical measure in oncology research.

This article highlights the significant progress being made in the field of immunotherapy and the potential impact of bispecific antibodies targeting PD1 or PD-L1 and VEGF. As researchers continue to explore and develop new treatments, the future of cancer therapy looks promising.

See also  OpenAI in hospitals, opioid recovery
TAGGED:BioNTechbreastcancerDatanegativepromisingTreatmenttriple
Share This Article
Twitter Email Copy Link Print
Previous Article Bernie Kaminski Invokes Decades Past Through Papier-Mâché Objects — Colossal Bernie Kaminski Invokes Decades Past Through Papier-Mâché Objects — Colossal
Next Article The sun may spit out giant solar flares more often than we thought The sun may spit out giant solar flares more often than we thought
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

Miniature Neutrino Detector Catches Elusive Particles at Nuclear Reactor

Physicists have made a breakthrough in neutrino detection with the development of a miniature neutrino…

August 1, 2025

Secured Self Visa Card: A basic credit-builder card with a low minimum deposit

Having a low credit score or lacking a credit history can complicate tasks like renting…

October 13, 2025

President Donald J. Trump Brings Home More Billion Dollar Deals During State Visit to the Republic of Korea – The White House

SEALING BILLIONS IN EXPORTS AND INVESTMENTS: Today, President Donald J. Trump wrapped up his significant…

October 29, 2025

Twenty years strong: a love letter to JS

JS, a leading tech media company, is celebrating its 20th anniversary. As someone who has…

June 11, 2025

Carville Debuts Absurd New Theory About Trump Stealing 2026 Midterms, O’Reilly Rips Him to Shreds Over it |

Carville's Stark Warning: Martial Law on the Horizon? On Wednesday, Democratic strategist James Carville suggested…

July 5, 2025

You Might Also Like

Medicare, midterm elections, Vinay Prasad: Morning Rounds
Health and Wellness

Medicare, midterm elections, Vinay Prasad: Morning Rounds

October 31, 2025
Remission achievable for 1 in 3 Indian diabetics through intensive app-based lifestyle program, study suggests
Health and Wellness

Remission achievable for 1 in 3 Indian diabetics through intensive app-based lifestyle program, study suggests

October 31, 2025
Once Again A Blood Pressure Medication Recall For Cancer Concerns
Health and Wellness

Once Again A Blood Pressure Medication Recall For Cancer Concerns

October 31, 2025
IVF research, FDA vouchers, dementia: Morning Rounds
Health and Wellness

IVF research, FDA vouchers, dementia: Morning Rounds

October 31, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?